{
    "root": "35d366c4-22fb-2cca-e063-6394a90a6980",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sucralfate",
    "value": "20250523",
    "ingredients": [
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "DIMETHICONE",
            "code": "92RU3N3Y1O",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11074"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R",
            "drugbank_id": "https://go.drugbank.com/drugs/DB01638"
        },
        {
            "name": "METHYLCELLULOSE, UNSPECIFIED",
            "code": "Z944H5SN0H",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "SUCRALFATE",
            "code": "XX73205DH5",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9313"
        }
    ],
    "indications": {
        "text": "sucralfate oral suspension indicated short-term ( 8 weeks ) treatment active duodenal ulcer .",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "active duodenal ulcer : recommended adult oral duodenal ulcer 1 gram ( 10 ml ) four times per day . sucralfate oral suspension administered empty stomach . antacids may prescribed needed relief pain taken within one-half hour sucralfate oral suspension . healing sucralfate may occur first week two , treatment continued 4 8 weeks unless healing demonstrated x-ray endoscopic examination . elderly : general , dose selection elderly patient cautious , usually starting low end dosing range , reflecting greater frequency decreased hepatic , renal , cardiac function , concomitant disease therapy ( , geriatric ) . call doctor medical advice side effects . may report side effects ingenus pharmaceuticals , llc 1-877-748-1970 fda 1-800-fda-1088 www.fda.gov/medwatch .",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "sucralfate oral suspension 1 g/10 ml pink suspension supplied bottles 420 ml ( ndc 54738-005-42 ) . shake well using . avoid freezing . store controlled room temperature 20-25\u00b0c ( 68-77\u00b0f ) [ usp ] . rx manufactured : richmond pharmaceuticals , inc. richmond , va 23233 revised : february 2025",
    "adverseReactions": "sucralfate oral suspension contraindicated patients known hypersensitivity active substance excipients .",
    "indications_original": "Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.",
    "contraindications_original": "Active Duodenal Ulcer:The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach.\n\n \n                  Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension.\n                  While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.\n                  \n                     Elderly:In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see\n \n  \n                        PRECAUTIONS, Geriatric Use\n                     ).\n\n \n                  Call your doctor for medical advice about side effects. You may report side effects to Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.",
    "warningsAndPrecautions_original": "Sucralfate Oral Suspension 1 g/10 mL is a pink suspension supplied in bottles of 420 mL\n                  (NDC 54738-005-42).\n                  \n                  \n                     SHAKE WELL BEFORE USING. AVOID FREEZING.\n                  \n                  Store at controlled room temperature 20-25\u00b0C (68-77\u00b0F)[see USP].\n                  Rx Only\n                  \n                     Manufactured for:\n                  \n                  Richmond Pharmaceuticals, Inc.\n                  Richmond, VA 23233\n                  Revised: February 2025",
    "adverseReactions_original": "Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.",
    "drug": [
        {
            "name": "Sucralfate",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9313"
        }
    ]
}